Discovery of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor: Design, synthesis, and anti-proliferative activities
作者:Honggang Xiang、Yanmei Chen、Jifa Zhang、Jin Zhang、Dabo Pan、Bo Liu、Liang Ouyang
DOI:10.1016/j.cclet.2020.03.017
日期:2020.6
Sodium taurocholate cotransporting polypeptide (NTCP) is identified as the functional receptor for HBV entry, which is responsible for upregulated HBV transcription in the HBV life cycle. Besides, NTCP is also implicated in the progression of HBV-induced hepatocellular carcinoma (HCC). Thereby, NTCP-targeting entry inhibitors are proposed to suppress HBV infection and replication in HBV-induced hepatoma
摘要牛磺胆酸钠共转运多肽(NTCP)被确定为HBV进入的功能受体,它负责HBV生命周期中HBV转录的上调。此外,NTCP还与HBV诱导的肝细胞癌(HCC)的进展有关。因此,提出了靶向NTCP的进入抑制剂以抑制HBV诱导的肝癌治疗中的HBV感染和复制。本文中,我们通过计算机筛选和化学合成相结合,获得了一种小分子NTCP抑制剂B7,该抑制剂对HepG2细胞表现出适度的抗增殖活性,并在体外具有抗HBV活性。此外,CETSA分析,分子对接和MD模拟验证了B7可以与NTCP结合。此外,免疫印迹分析表明,B7诱导HepG2细胞凋亡,其中Bax和caspase 3裂解的表达增加,而Bcl-2的表达减少。综上所述,我们的研究确定B7是具有抗增殖活性的新型NTCP抑制剂,这可能为HCC治疗提供新的机会。